Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Eur J Gynaecol Oncol ; 35(1): 32-8, 2014.
Article in English | MEDLINE | ID: mdl-24654458

ABSTRACT

PURPOSE OF INVESTIGATION: To describe the experience of ovarian cancer patients from symptoms complained before diagnosis until the impact of ovarian cancer diagnosis perceived by women. MATERIALS AND METHODS: The authors used the Psychological General Well being Index (PGWBI) and a semi-structured interview to measure the overall well being of 39 women diagnosed with ovarian cancer in the period 2005-2010 at a secondary care hospital in northern Italy. RESULTS: The PGWBI showed that the majority of the women reported general stress. On the semi-structured interview, 95% of women reported having symptoms and 69% reported a stressful event prior to diagnosis. More than 50% of women reported changes concerning life course. Almost all reported that their primary concerns had to do with the surgical scar, weight gain, and hair loss. CONCLUSIONS: Ovarian cancer diagnosis has a very stressful effect on the quality of life. Early assessment of psychological problems must be an integral part of the therapeutic pathway. Gynaecologists must provide clear and useful information regarding the disease itself as well as regarding correlated symptom relief.


Subject(s)
Neoplasms, Glandular and Epithelial/psychology , Ovarian Neoplasms/psychology , Adult , Aged , Anxiety/etiology , Carcinoma, Ovarian Epithelial , Cohort Studies , Depression/etiology , Fatigue/etiology , Female , Humans , Italy/epidemiology , Middle Aged , Neoplasms, Glandular and Epithelial/diagnosis , Neoplasms, Glandular and Epithelial/epidemiology , Ovarian Neoplasms/diagnosis , Ovarian Neoplasms/epidemiology , Quality of Life , Surveys and Questionnaires
2.
Eur J Gynaecol Oncol ; 32(3): 350-2, 2011.
Article in English | MEDLINE | ID: mdl-21797134

ABSTRACT

BACKGROUND: Primary endometrial squamous cell carcinoma (PSECC) is a rare neoplasm. Squamous epithelium derived from endometrioid cancer or from cervical squamous cell carcinoma. The prevalence is about 0.1%. The genesis, histogenesis and biological behavior are unknown. CASE PRESENTATION: A 48-year old woman in postmenopause, referring pelvic pain and vaginal bleeding. Transvaginal ultrasound showed a bulky uterus with the endometrium containing an hyperecogenic area. Endometrial biopsy found an epidermoid carcinoma. MRI showed a 4 x 2 x 1.2 cm mass occupying the uterine cavity. The patient underwent radical treatment. Pathological examination showed features of PSECC. The mutation of p53 tumor suppressor protein was disclosed in 15% of neoplastic cells. PCR revealed the absence of HPV DNA. CONCLUSIONS: The findings of our case move us to underline that the pathogenesis of this tumor is still unclear. Moreover, preoperative diagnosis and staging of PESCC is extremely difficult. Most patients do not show characteristic symptoms and predisposing factors, making it almost impossible to diagnose the precise localization of tumor origin.


Subject(s)
Carcinoma, Squamous Cell/pathology , Endometrial Neoplasms/pathology , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/surgery , Endometrial Neoplasms/genetics , Endometrial Neoplasms/surgery , Female , Humans , Middle Aged , Postmenopause , Treatment Outcome , Tumor Suppressor Protein p53/genetics
3.
Eur J Gynaecol Oncol ; 31(1): 109-13, 2010.
Article in English | MEDLINE | ID: mdl-20349795

ABSTRACT

BACKGROUND: Malignant melanoma metastases to the female genital tract in only 2.5% of cases. Melanoma is characterized by clinical variability and unpredictable biological behavior with long remissions and relapses that develop rapidly. CASE AND REVIEW: A 57-year-old woman was admitted for hypogastric pain and weight loss. She had presented enucleation of the right eye six years before for malignant choroid melanoma. Gynaecological examination revealed enlarged ovaries. Bilateral salpingo-oophorectomy, hysterectomy, and omentectomy were performed. Final pathology diagnosed a choroidal metastatic melanoma (CMM). The patient died seven months later. Only seven cases of CMM have been reported in the literature. Patients affected by CMM ranged in age from 38 to 83 years (median 51.2 years), the time to relapse ranged from 3-25 years (median 51.2 years), the size of the cysts ranged from 4-17 cm (median 9.7 cm) and the survival period ranged from 2-14 months (median 8.1 months). CONCLUSION: Malignant melanoma is misdiagnosed because of lack of discriminatory symptoms, increased tumor markers, characteristic imaging findings and the capacity to mimic other tumors. Today CMM still represents a challenge for gynecologic oncologists.


Subject(s)
Choroid Neoplasms/pathology , Melanoma/secondary , Ovarian Neoplasms/secondary , Female , Humans , Melanoma/diagnosis , Middle Aged , Ovarian Neoplasms/diagnosis
4.
Eur J Gynaecol Oncol ; 30(1): 106-9, 2009.
Article in English | MEDLINE | ID: mdl-19317272

ABSTRACT

BACKGROUND: Malignant melanoma (MM) accounts for 3% of cancers that affect women and results in less than 1% of cancer deaths. It is characterized by clinical variability and unpredictable biological behavior. Fewer than ten cases of amelanotic MM (AMM) have been reported in literature. CASE: A 61-year-old woman was admitted for vaginal spotting. A huge, soft cervix with an exophytic lesion was biopsied. A clear cell carcinoma, FIGO Stage IB1, was diagnosed and radically treated. The final pathology showed an AMM of the cervix positive for PAS and HMB 45. The patient is clinically free of disease ten years postoperatively. CONCLUSION: Malignant melanoma of the cervix is often misdiagnosed because of non discriminatory features and the capacity to mimic other tumors. Malignant melanoma of the cervix needs to be diagnosed as quickly as possible because a timely therapy and a long and careful follow-up might result in better survival.


Subject(s)
Melanoma, Amelanotic/pathology , Skin Neoplasms/pathology , Uterine Cervical Neoplasms/pathology , Female , Humans , Melanoma, Amelanotic/surgery , Middle Aged , Sentinel Lymph Node Biopsy , Skin Neoplasms/surgery , Survivors , Uterine Cervical Neoplasms/surgery
5.
Anticancer Res ; 28(4C): 2309-15, 2008.
Article in English | MEDLINE | ID: mdl-18751411

ABSTRACT

BACKGROUND: Primary retroperitoneal mucinous cystadenoma is a rare tumor only 48 cases have been reported in international literature. Patients affected by primary retroperitoneal mucinous cystadenoma/cystadenocarcinoma ranged in age from 17 to 86 years (median, 42.3 years) and the size of the cystis ranged from 5 to 35 cm (median, 16.1 cm). There is no unanimous opinion on the genesis of these tumors and, due to their extreme rarity, its histogenesis, biological behavior and the optimal management strategy remain at a speculative level. CASE REPORT: We report the case of a huge borderline primary retroperitoneal mucinous cystadenoma (24 x 25 cm) in a 35-year-old woman and the strategies adopted for the diagnosis and surgical management. CONCLUSION: Primary mucinous cystic tumor of the retroperitoneum was correctly diagnosed only at the time of surgery. As well as in the majority of cases reported in the literature, preoperative investigations were not able to give information about the tumor site. In spite of the short follow-up (two years), the patient's favorable course supports the hypothesis that primary retroperitoneal mucinous cystadenoma may be treated in the same manner as a primary ovarian tumor of the same grade and comparable stage.


Subject(s)
Cystadenoma, Mucinous/diagnosis , Ovarian Neoplasms/diagnosis , Retroperitoneal Neoplasms/diagnosis , Adult , Cystadenoma, Mucinous/pathology , Cystadenoma, Mucinous/surgery , Diagnosis, Differential , Female , Humans , Ovarian Neoplasms/pathology , Ovarian Neoplasms/surgery , Retroperitoneal Neoplasms/pathology , Retroperitoneal Neoplasms/surgery
6.
Int J Gynecol Cancer ; 18(5): 1127-31, 2008.
Article in English | MEDLINE | ID: mdl-18028380

ABSTRACT

Mesonephric adenocarcinoma deriving from remnants of vaginal mesonephric ducts is one of the rarest tumors of the female genital tract with only three cases reported till date in international literature. Differential diagnosis from other aggressive tumors is complex and controversies exist in the literature regarding the biological behavior, prognosis, and optimal management strategies of these tumors. A 58-year-old woman presented with a large mass extending from the right adnexal region to the perineum and labia majora. CA125 was increased. A radical excision of the lesion with pelvic and para-aortic lymphadenectomy was performed. A well-capsulated mesonephric adenocarcinoma in a background of vaginal mesonephric remnants was diagnosed. Tumor cells showed immunoreactivity for pancytokeratin, cytokeratin (CK), CD 10, epithelial membrane antigen, vimentin, and calretinin; indeed they were negative for carcinoembryonic antigen, CK 20, estrogen receptor, and progesterone receptor. No evidence of lymph node involvement or metastatic disease was observed. The patient did not receive any adjuvant therapy and is alive and clinically free of disease at 1-year follow-up. In spite of the aggressive biological behavior attributed in literature to mesonephric carcinomas, which is probably due to the complex differential diagnosis with other müllerian tumors, the favorable course of our patient further supports the hypothesis that malignant mesonephric carcinomas may not behave aggressively and that radical surgery alone may be curative.


Subject(s)
Adenocarcinoma/pathology , Mesonephroma/pathology , Vaginal Neoplasms/pathology , Adenocarcinoma/diagnostic imaging , Adenocarcinoma/surgery , Female , Follow-Up Studies , Humans , Immunohistochemistry , Mesonephroma/diagnostic imaging , Mesonephroma/surgery , Middle Aged , Time Factors , Tomography, X-Ray Computed , Vaginal Neoplasms/diagnostic imaging , Vaginal Neoplasms/surgery
7.
J Endocrinol Invest ; 28(9): 827-30, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16370564

ABSTRACT

BACKGROUND: Struma ovarii is the most common monodermal ovarian teratoma and consists mainly of thyroid tissue. Only 5% of patients with this tumor have features of hyperthyroidism. The pathophysiology of hyperthyroidism in struma ovarii is not clear. CASE: We describe a case of benign struma ovarii, presenting with the clinical features of an ovarian cancer: large complex pelvic mass, large amount of ascites and markedly elevated CA-125 serum levels. The patient was initially treated for Graves' disease, on the basis of ultrasonographic, laboratoristic and scintigraphic evidence. The resistance to the medical treatment led to thyroidectomy. After surgery the hyperthyroidism persisted and, suddenly, the patient presented ascites. A large pelvic mass was then diagnosed which, at the pathologic examination, was diagnosed as a struma ovarii. CONCLUSION: The struma ovarii always has to be considered when a pelvic mass is associated with features of hyperthyroidism.


Subject(s)
CA-125 Antigen/blood , Graves Disease/etiology , Graves Disease/therapy , Ovarian Neoplasms/etiology , Ovarian Neoplasms/surgery , Struma Ovarii/etiology , Struma Ovarii/surgery , Adult , Ascites/surgery , Female , Graves Disease/diagnosis , Humans , Hyperthyroidism/etiology , Methimazole/therapeutic use , Ovariectomy , Struma Ovarii/diagnosis , Thyroidectomy , Thyroxine/therapeutic use
8.
J Endocrinol Invest ; 28(10 Suppl): 80-4, 2005.
Article in English | MEDLINE | ID: mdl-16550729

ABSTRACT

Post-menopausal osteoporosis represents a major public health problem. Osteoporotic fractures in older women constitute a major cause of disability, mortality and economic burden. Cardiovascular disease (CVD) is the primary cause of death in women in westernized countries, with more than one in two women dying from CVD. In literature it is well established that an early menopause increases the risk of CVD and that a later menopause is associated with longer overall survival. Until a few years ago, in the management guidelines, a combination of lifestyle and use of hormonal replacement therapy (HRT) was suggested to reduce the CVD risk in post-menopausal women. However, recent studies such as the Women's Health Initiative (WHI) trial and the Heart and Estrogen/Progestin Replacement Study (HERS) I and II has forced practitioners to reconsider their options for prevention of CVD in post-menopausal women. The increased risk of CVD and stroke which were not counterbalanced by the smaller reduction in numbers of hip fractures in the WHI and in the HERS I-II suggest new characteristics of women in which HRT could possibly exert a favourable risk/benefit ratio. The use of HRT in post-menopausal women might be considered in symptomatic women and it might be individualized for each patients. Therefore, for cardiovascular and osteoporosis risk, regular prevention programmes should serve the needs of middle-aged women.


Subject(s)
Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/physiopathology , Estrogen Replacement Therapy , Osteoporosis, Postmenopausal/epidemiology , Osteoporosis, Postmenopausal/physiopathology , Aged , Aged, 80 and over , Aging/blood , Bone Density/drug effects , Cardiovascular Diseases/drug therapy , Cardiovascular Diseases/prevention & control , Estrogens/blood , Estrogens/pharmacology , Estrogens/therapeutic use , Female , Hip Fractures/physiopathology , Hip Fractures/prevention & control , Humans , Middle Aged , Osteoporosis, Postmenopausal/drug therapy , Osteoporosis, Postmenopausal/prevention & control , Progestins/blood , Progestins/pharmacology , Progestins/therapeutic use , Risk Assessment , Risk Factors
9.
Gynecol Endocrinol ; 17(1): 45-9, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12724018

ABSTRACT

The aim of our study was to evaluate the effects of isoflavones on climacteric-related symptoms and on the endometrium in postmenopausal women, in a prospective, open, randomized, clinical trial performed at the Menopause Clinic of our Department. Seventy postmenopausal women were randomly assigned to two treatment groups receiving 12 cycles of treatment with genistein (group A) or calcium (group B). In all patients ultrasonographic endometrial thickness and Kupperman Index (KI) were evaluated at baseline and after 6 and 12 cycles of treatment. At baseline no significant difference was detected in endometrial thickness and in KI between groups A and B. After 6 and 12 cycles of treatment, no significant difference was observed in endometrial thickness between or within groups. Endometrial thickness was lower than 5 mm in all cases before and during treatment except in two cases in group B and in one case in group A after 12 months. At 6 and 12 months, the KI was significantly (p < 0.05) lower in group A in comparison with baseline values and group B. We conclude that genistein administration reduces climacteric symptoms in postmenopausal women and does not increase endometrial thickness.


Subject(s)
Endometrium/drug effects , Endometrium/diagnostic imaging , Genistein/administration & dosage , Genistein/adverse effects , Biopsy , Calcium/administration & dosage , Climacteric/drug effects , Endometrium/anatomy & histology , Female , Humans , Middle Aged , Postmenopause , Prospective Studies , Ultrasonography
SELECTION OF CITATIONS
SEARCH DETAIL
...